A cell-based screen for inhibitors of protein folding and degradation

[1]  M. Drysdale,et al.  Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. , 2009, Journal of medicinal chemistry.

[2]  P. Workman,et al.  Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. , 2008, Cancer cell.

[3]  J. Bradner,et al.  HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. , 2008, Blood.

[4]  Tony Taldone,et al.  Targeting Hsp90: small-molecule inhibitors and their clinical development. , 2008, Current opinion in pharmacology.

[5]  Tony Taldone,et al.  Design of a fluorescence polarization assay platform for the study of human Hsp70. , 2008, Bioorganic & medicinal chemistry letters.

[6]  J. Brueggen,et al.  NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models , 2008, Breast Cancer Research.

[7]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[8]  R. Svensson,et al.  Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. , 2007, Cancer research.

[9]  S. Kasibhatla,et al.  Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. , 2007, Journal of medicinal chemistry.

[10]  P. Workman,et al.  A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation , 2007, Molecular Cancer Therapeutics.

[11]  L. Pearl,et al.  In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. , 2007, Cancer research.

[12]  N. Rosen,et al.  An acetylation site in the middle domain of Hsp90 regulates chaperone function. , 2007, Molecular cell.

[13]  C. Erlichman,et al.  Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. , 2006, Cancer research.

[14]  Neal Rosen,et al.  Hsp90: a novel target for cancer therapy. , 2006, Current topics in medicinal chemistry.

[15]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[16]  S. Westerheide,et al.  Triptolide, an Inhibitor of the Human Heat Shock Response That Enhances Stress-induced Cell Death* , 2006, Journal of Biological Chemistry.

[17]  D. Sawyer,et al.  Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.

[18]  M. Sherman,et al.  Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. , 2006, Cancer research.

[19]  K. Bhalla,et al.  Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. , 2005, Cancer research.

[20]  T. Yao,et al.  Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone* , 2005, Journal of Biological Chemistry.

[21]  Daniel Kaganovich,et al.  Protein quality control: chaperones culling corrupt conformations , 2005, Nature Cell Biology.

[22]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[23]  Y. Miyata,et al.  Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. , 2005, Current pharmaceutical design.

[24]  L. Petrucelli,et al.  Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. , 2005, Current Alzheimer research.

[25]  N. Rosen,et al.  Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90 , 2004, Journal of biomolecular screening.

[26]  S. Gillies,et al.  Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) , 2004, Cancer biology & therapy.

[27]  L. Neckers,et al.  Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. , 2004, Molecular cancer therapeutics.

[28]  Gregor P Lotz,et al.  Aha1 Binds to the Middle Domain of Hsp90, Contributes to Client Protein Activation, and Stimulates the ATPase Activity of the Molecular Chaperone* , 2003, The Journal of Biological Chemistry.

[29]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[30]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  H. Itoh,et al.  A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. , 1999, The Biochemical journal.

[32]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[33]  S. Lindquist,et al.  Cdc37 is a molecular chaperone with specific functions in signal transduction. , 1997, Genes & development.

[34]  J. Dong,et al.  Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Nathan,et al.  In vivo analysis of the Hsp90 cochaperone Sti1 (p60) , 1997, Molecular and cellular biology.

[36]  F. Boschelli,et al.  CDC37 is required for p60v-src activity in yeast. , 1996, Molecular biology of the cell.

[37]  P. Cohen,et al.  The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. , 1995, The Biochemical journal.

[38]  S. Lindquist,et al.  Role of the protein chaperone YDJ1 in establishing Hsp90-mediated signal transduction pathways. , 1995, Science.

[39]  B. Sefton,et al.  Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia , 1994, Molecular and cellular biology.

[40]  S. Lindquist,et al.  Heat-shock protein hsp90 governs the activity of pp60v-src kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Jove,et al.  Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system. , 1992, The Journal of biological chemistry.

[42]  P. Wendler,et al.  Src homology 2 domain deletion mutants of p60v-src do not phosphorylate cellular proteins of 120-150 kDa. , 1989, Oncogene.

[43]  T. Hunter,et al.  Phosphorylation and metabolism of the transforming protein of Rous sarcoma virus , 1982, Journal of virology.

[44]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: current status. , 2006, Advances in cancer research.

[45]  J. Bradner,et al.  INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS , 2005 .

[46]  Holly McDonough,et al.  CHIP: a link between the chaperone and proteasome systems , 2003, Cell stress & chaperones.

[47]  T. Fojo,et al.  The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy , 2001, Leukemia.

[48]  W. Bruening,et al.  Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. , 1998, Nucleic acids research.

[49]  F. Boschelli,et al.  The Ydj1 molecular chaperone facilitates formation of active p60v-src in yeast. , 1996, Molecular biology of the cell.

[50]  W. Foye.  Cancer chemotherapeutic agents , 1995 .

[51]  S. Lindquist,et al.  The heat-shock proteins. , 1988, Annual review of genetics.